Neurological
Refine Search
Biotechnology
The US Food and Drug Administration has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). 12 April 2017
Biotechnology
David Hung, the founder and former chief executive of Medivation, an oncology-focused biopharma bought by US pharma giant Pfizer for $14 billion last year, has switched his attention to dementia in his role. 11 April 2017
Biotechnology
USA-based Marinus Pharmaceuticals, a biotech company focused on developing treatments for epilepsy and neuropsychiatric disorders, has appointed Lorianne Masuoka as chief medical officer. 11 April 2017
Biotechnology
Ireland’s Health Service Executive (HSE) National Drugs Management Program (NDMP) and Neurology Program have introduced a national reimbursement scheme which will facilitate access for patients with multiple sclerosis (MS) to approved high cost treatments. 7 April 2017
Pharmaceutical
Botox (onabotulinumtoxinA), a treatment which made its name for its aesthetic potential in reducing facial wrinkles, is to be taken into Phase III trials in major depressive disorder (MDD). 7 April 2017
Generics
On April 6, 2017, the British Court of Appeal upheld Flynn Pharma’s right to stop the parallel importation into the UK of Pfizer’s Epanutin (phenytoin sodium) anti-epileptic drug for resale as Phenytoin Sodium Flynn. 7 April 2017
Pharmaceutical
Briviact (brivaracetam) has been accepted for use in Ireland as an add-on treatment for partial onset seizures (POS) with or without secondary generalized seizures in adults with epilepsy. 6 April 2017
Pharmaceutical
Ligand Pharmaceuticals has entered into commercial license and supply agreements with Marinus Pharmaceuticals, granting rights to use Ligand’s Captisol in the formulation of its intravenous (IV) ganaxolone. 6 April 2017
Pharmaceutical
Japanese drugmakers Eisai and Meiji Seika Pharma have entered into a license agreement for the commercialization of ME2125 (safinamide) for the treatment of Parkinson’s disease in Japan and Asia. 5 April 2017
Generics
Mallinckrodt has reached an agreement in principle with the US Drug Enforcement Administration (DEA) and the US Attorneys' Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York regarding controlled substances. 4 April 2017
Pharmaceutical
The US Food and Drug Administration has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease, Teva Pharmaceutical has announced. 4 April 2017
Biotechnology
Belgian pharma company UCB has entered into a collaboration with Q-State Biosciences, an American firm, to discover new therapeutics. 4 April 2017
Biotechnology
Ireland-headquartered Shire has announced that its partner in Japan, Shionogi , has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv (guanfacine hydrochloride prolonged release). 4 April 2017
Pharmaceutical
Vtesse, a privately-held US rare disease company, has been acquired in a deal valuing the firm at around $200 million. 3 April 2017
Biotechnology
A US patent court has ruled that Biogen's patents on its blockbuster multiple sclerosis drug Tecfidera (dimethyl fumarate) are valid. 3 April 2017
Pharmaceutical
Most of the headline grabbing news last week focussed on approvals of new medicines and some exciting clinical trial results. Among these were the approvals of Roche’s Ocrevus for multiple sclerosis, Tesaro’s Zejula for treatment of recurrent ovarian cancer and Sanofi’s Dupixent for atopic dermatitis. Also stirring interest was clinical data on Vertex’ combination of tezacaftor and ivacaftor. 2 April 2017
Biotechnology
The US Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). 29 March 2017
Pharmaceutical
Newron Pharmaceuticals has released positive detailed results of a Phase IIa study with its unique sodium channel blocker, evenamide (NW-3509), in patients with schizophrenia. 27 March 2017
Generics
Biogaran, the leading company in France’s generics market, has announced the takeover of all activities of Nigerian firm Swipha in the African country. 27 March 2017
Pharmaceutical
The new US President Donald Trump suffered a major defeat on Friday, as his flagship legislation to repeal what is commonly referred to as Obamacare, failed to gain sufficient support. Also making headlines was Eli Lilly’s planned investment on infrastructure; a promising abuse-deterrent opioid drug; recommended European approval of a new hemophilia drug; and a setback for Novartis’ serelaxin. 25 March 2017
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze